MedTrace Logo

Auto/Allo Tandem Transplant for Relapsed B-NHL

NCT03205657 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2023-11-07

No results posted yet for this study

Summary

The investigators plan to perform a retrospective review of patients with poor risk relapsed/refractory B-NHL having received HSCT and targeted immunotherapy at the Maria Fareri Children's Hospital between January 1, 2012 and June 1, 2015. The investigators will review the clinical records and collect the data with de-identified medical information from our HSCT clinical research database.

Conditions

  • Non Hodgkin Lymphoma

Interventions

PROCEDURE

auto transplant followed by allo transplant

patients who got MAC conditioning with auto SCT followed by RIC followed by alloSCT for mature B-NHL

Sponsors & Collaborators

  • New York Medical College

    lead OTHER

Principal Investigators

  • Mitchell Cairo, MD · New York Medical College

Eligibility

Min Age
0 Years
Max Age
29 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-01
Primary Completion
2021-12-31
Completion
2022-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03205657 on ClinicalTrials.gov